News

Obesity Drugs' CV Risk Assessment Needs Hard End Points

Publish date: April 5, 2012

 

FROM A MEETING OF THE FDA'S ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE

"That makes perfect sense to me. I’ll go along with that," said Dr. Michael A. Proschan of the National Institute of Allergy and Infectious Diseases in Bethesda, Md. That "sounds like a reasonable idea," Erica Brittain, Ph.D., also of NIAID, agreed.

Cathy Dombrowski is with "The Pink Sheet." Both this news organization and "The Pink Sheet" are owned by Elsevier.

Pages

Recommended Reading

FDA Says Weight Loss Drug Needs CV Outcome Trial
MDedge Internal Medicine
Her Chief Complaint Is ... And by the Way She’s Also Pregnant
MDedge Internal Medicine
FDA Panel Endorses Obesity Drug Qnexa After All
MDedge Internal Medicine
Memory Changes, Hyperglycemia Prompt Statin Label Changes
MDedge Internal Medicine
Duodenal Switch May Excel at Type 2 Diabetes Resolution
MDedge Internal Medicine
Slight Hyperglycemia Risk Shouldn't Deter Statin Use
MDedge Internal Medicine
Arthritis Plus Hypothyroidism Ups Women's CVD Risk
MDedge Internal Medicine
Bariatric Surgery Bests Medication In Obese Diabetics
MDedge Internal Medicine
Gout Prevalence Has Spiked
MDedge Internal Medicine
Novel Agent Lowered LDL Up to 72%
MDedge Internal Medicine